Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscle

Archives of Physiology and Biochemistry

Volumn 120, Issue 2, 2014, Pages 64-72

  Wiza, Claudia ^a,b   Chadt, Alexandra ^a,b   Blumensatt, Marcel ^a,b   Kanzleiter, Timo ^b,c   Herzfeld De Wiza, Daniella ^a,b   Horrighs, Angelika ^a,b   Mueller, Heidi ^a,b   Nascimento, Emmani B M ^d   Schürmann, Annette ^b,c   Al Hasani, Hadi ^a,b   Ouwens, D Margriet ^a,b,e  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b German Centre for Diabetes Research (DZD)   (Germany)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Akt; Insulin sensitivity; IRS1; MTORC1; PRAS40; Proteasome

Indexed keywords

AKT1S1 PROTEIN, HUMAN; INSULIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEASOME; PROTEIN KINASE B; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANIMAL; ARTICLE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; HYPERINSULINISM; INSULIN RESISTANCE; MALE; METABOLISM; MOUSE; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANIMALS; GENE EXPRESSION; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MALE; MICE; MULTIPROTEIN COMPLEXES; MUSCLE, SKELETAL; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84910118644     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.3109/13813455.2014.894076     Document Type: Article

References (33)

1. Carlotti F, Bazuine M, Kekarainen T, et al. (2004). Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol Ther, 9, 209-17.
2. Cleasby ME, Davey JR, Reinten TA, et al. (2005). Acute bidirectional manipulation of muscle glucose uptake by in vivo electrotransfer of constructs targeting glucose transporter genes. Diabetes, 54, 2702-11.
3. Cleasby ME, Reinten TA, Cooney GJ, et al. (2007). Functional studies of Akt isoform specificity in skeletal muscle in vivo; maintained insulin sensitivity despite reduced insulin receptor substrate-1 expression. Mol Endocrinol, 21, 215-28.
4. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. (1985). Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest, 76, 149-55.
5. Dey N, Ghosh-Choudhury N, Das F, et al. (2010). PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy. J Cell Physiol, 225, 27-41.
6. Fonseca BD, Smith EM, Lee VH, et al. (2007). PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem, 282, 24514-24.
7. Harrington LS, Findlay GM, Gray A, et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol, 166, 213-23.
8. Hoehn KL, Hohnen-Behrens C, Cederberg A, et al. (2008). IRS1- independent defects define major nodes of insulin resistance. Cell Metab, 7, 421-33.
9. Jazet IM, Schaart G, Gastaldelli A, et al. (2008). Loss of 50% of excess weight using a very low energy diet improves insulinstimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia, 51, 309-19.
10. Laplante M, Sabatini DM. (2012). mTOR signaling in growth control and disease. Cell, 149, 274-93.
11. Mir LM, Bureau MF, Gehl J, et al. (1999). High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA, 96, 4262-7.
12. Nadler ST, Stoehr JP, Rabaglia ME, et al. (2001). Normal Akt/PKB with reduced PI3K activation in insulin-resistant mice. Am J Physiol Endocrinol Metab, 281, E1249-54.
13. Nascimento EB, Fodor M, van der Zon GC, et al. (2006). Insulinmediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes, 55, 3221-8.
14. Nascimento EB, Snel M, Guigas B, et al. (2010). Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signal, 22, 961-7.
15. Oshiro N, Takahashi R, Yoshino K, et al. (2007). The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem, 282, 20329-39.
16. Pallares-Cartes C, Cakan-Akdogan G, Teleman AA. (2012). Tissuespecific coupling between insulin/IGF and TORC1 signaling via PRAS40 in Drosophila. Dev Cell, 22, 172-82.
17. Pirola L, Bonnafous S, Johnston AM, et al. (2003). Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signaling pathways in L6 muscle cells. J Biol Chem, 278, 15641-51.
18. Samuel VT, Shulman GI. (2012). Mechanisms for insulin resistance: common threads and missing links. Cell, 148, 852-71.
19. Sancak Y, Thoreen CC, Peterson TR, et al. (2007). PRAS40 is an insulinregulated inhibitor of the mTORC1 protein kinase. Mol Cell, 25, 903-15.
20. Satkauskas S, Bureau MF, Puc M, et al. (2002). Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol Ther, 5, 133-40.
21. Sell H, Laurencikiene J, Taube A, et al. (2009). Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes, 58, 2731-40.
22. Shanik MH, Xu Y, Skrha J, et al. (2008). Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care, 31 Suppl 2, S262-8.
23. Shulman GI, Rothman DL, Jue T, et al. (1990). Quantitation of muscle glycogen synthesis in normal subjects and subjects with noninsulin- dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med, 322, 223-8.
24. Thedieck K, Polak P, Kim ML, et al. (2007). PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One, 2, e1217.
25. Tremblay F, Krebs M, Dombrowski L, et al. (2005). Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes, 54, 2674-84.
26. Tzatsos A. (2009). Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR. J Biol Chem, 284, 22525-34.
27. Vander Haar E, Lee SI, Bandhakavi S, et al. (2007). Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol, 9, 316-23.
28. Wang L, Harris TE, Lawrence Jr JC. (2008). Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation. J Biol Chem, 283, 15619-27.
29. Wang L, Harris TE, Roth RA, Lawrence Jr JC. (2007). PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem, 282, 20036-44.
30. Wiza C, Herzfeld de WD, Nascimento EB, et al. (2013a). Knockdown of PRAS40 inhibits insulin action via proteasome-mediated degradation of IRS1 in primary human skeletal muscle cells. Diabetologia, 56, 1118-28.
31. Wiza C, Nascimento EB, Linssen MM, et al. (2013b). Proline-rich Akt substrate of 40-kDa contains a nuclear export signal. Cell Signal, 25, 1762-8.
32. Wiza C, Nascimento EB, Ouwens DM. (2012). Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab, 302, E1453-60.
33. Zoncu R, Efeyan A, Sabatini DM. (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol, 12, 21-35.